A Phase III, Randomized, Double-blind, Placebo Controlled Study of Adagloxad Simolenin (OBI 822)/OBI 821 Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients, Defined as Residual Invasive Disease Following Neoadjuvant Chemotherapy OR ≥4 Positive Axillary Nodes
Phase of Trial: Phase III
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Adagloxad simolenin (Primary) ; OPT 821 (Primary)
- Indications Early breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors OBI Pharma
- 10 Dec 2018 Status changed from not yet recruiting to recruiting.
- 20 Sep 2018 Planned End Date changed from 31 Aug 2025 to 30 Nov 2025.
- 20 Sep 2018 Planned primary completion date changed from 31 Aug 2025 to 30 Nov 2025.